Want to see DE:SBS full AI Analyst Report?
STRATEC Biomedical (SBS) Stock Statistics & Valuation Metrics
Total Valuation
STRATEC Biomedical has a market cap or net worth of EUR 273.51M. The enterprise value is EUR 300.91M.
- Market Cap
- EUR 273.51M
- Enterprise Value
- EUR 300.91M
Share Statistics
STRATEC Biomedical has 12,157,841 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 12,157,841
- Owned by Insiders
- ―
- Owned by Institutions
- 6.04%
Financial Efficiency
STRATEC Biomedical’s return on equity (ROE) is -0.00 and return on invested capital (ROIC) is -0.10%.
- Return on Equity (ROE)
- -0.00
- Return on Assets (ROA)
- -0.00
- Return on Invested Capital (ROIC)
- -0.10%
- Return on Capital Employed (ROCE)
- 0.02
- Revenue Per Employee
- 181.39K
- Profits Per Employee
- -174.982
- Employee Count
- 1,383
- Asset Turnover
- 0.57
- Inventory Turnover
- 1.65
Valuation Ratios
The current PE Ratio of STRATEC Biomedical is -598.75. STRATEC Biomedical’s PEG ratio is 9.20.
- PE Ratio
- -598.75
- PS Ratio
- 1.19
- PB Ratio
- 1.22
- Price to FCF
- 11.06
- Price to Operating Cash Flow
- 8.31
- PEG Ratio
- 9.20
Income Statement
In the last 12 months, STRATEC Biomedical had revenue of 250.86M and earned -242.00K in profits. Earnings per share was -0.02.
- Revenue
- 250.86M
- Gross Profit
- 64.22M
- Operating Income
- 8.59M
- Pretax Income
- 4.85M
- Net Income
- -242.00K
- EBITDA
- 27.19M
- Earnings Per Share (EPS)
- -0.02
Cash Flow
In the last 12 months, operating cash flow was 35.05M and capital expenditures -8.72M, giving a free cash flow of 26.33M billion.
- Operating Cash Flow
- 35.05M
- Free Cash Flow
- 26.33M
- Free Cash Flow per Share
- 2.17
Dividends & Yields
STRATEC Biomedical pays an annual dividend of EUR 0.60, resulting in a dividend yield of 2.51%
- Dividend Per Share
- EUR 0.60
- Dividend Yield
- 2.51%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.04%
- Earnings Yield
- -0.14%
Stock Price Statistics
- Beta
- 1.37
- 52-Week Price Change
- 1.91%
- 50-Day Moving Average
- 23.38
- 200-Day Moving Average
- 19.73
- Relative Strength Index (RSI)
- 44.70
- Average Volume (3m)
- 12.61K
Important Dates
STRATEC Biomedical upcoming earnings date is Nov 12, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- Jun 24, 2026
Financial Position
STRATEC Biomedical as a current ratio of 3.97, with Debt / Equity ratio of 55.68%
- Current Ratio
- 3.97
- Quick Ratio
- 1.86
- Debt to Market Cap
- 0.44
- Net Debt to EBITDA
- 4.01
- Interest Coverage Ratio
- 2.13
Taxes
In the past 12 months, STRATEC Biomedical has paid 5.09M in taxes.
- Income Tax
- 5.09M
- Effective Tax Rate
- 1.05
Enterprise Valuation
STRATEC Biomedical EV to EBITDA ratio is 12.34, with an EV/FCF ratio of 14.73.
- EV to Sales
- 1.58
- EV to EBITDA
- 12.34
- EV to Free Cash Flow
- 14.73
- EV to Operating Cash Flow
- 11.06
Balance Sheet
STRATEC Biomedical has EUR 19.03M in cash and marketable securities with EUR 115.72M in debt, giving a net cash position of -EUR 96.69M billion.
- Cash & Marketable Securities
- EUR 19.03M
- Total Debt
- EUR 115.72M
- Net Cash
- -EUR 96.69M
- Net Cash Per Share
- -EUR 7.95
- Tangible Book Value Per Share
- EUR 10.37
Margins
Gross margin is 23.57%, with operating margin of 2.65%, and net profit margin of -0.16%.
- Gross Margin
- 23.57%
- Operating Margin
- 2.65%
- Pretax Margin
- 2.38%
- Net Profit Margin
- -0.16%
- EBITDA Margin
- 12.84%
- EBIT Margin
- 2.81%
Analyst Forecast
The average price target for STRATEC Biomedical is EUR 30.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 30.00
- Price Target Upside
- 25.26% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- 60
